Ken Griffin Chemo Centryx, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $4.24 Million - $9.92 Million	-191,443 Reduced 62.89%	112,981 $5.84 Million
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $29,276 - $52,434	-1,906 Reduced 0.62%	304,424 $7.54 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $5.21 Million - $9.17 Million	-234,282 Reduced 43.34%	306,330 $7.68 Million
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $7.7 Million - $17 Million	-419,075 Reduced 43.67%	540,612 $19.7 Million
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $3.13 Million - $4.71 Million	237,548 Added 32.9%	959,687 $16.4 Million
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $3.63 Million - $19.3 Million	378,759 Added 110.3%	722,139 $9.67 Million
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $11.4 Million - $15.7 Million	-229,691 Reduced 40.08%	343,380 $17.6 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $5.43 Million - $7.48 Million	114,846 Added 25.06%	573,071 $35.5 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $13.9 Million - $18.5 Million	-300,013 Reduced 39.57%	458,225 $25.1 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $918,705 - $1.55 Million	23,813 Added 3.24%	758,238 $43.6 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $22 Million - $34.2 Million	673,474 Added 1104.94%	734,425 $29.5 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $312,817 - $1.82 Million	45,935 Added 305.91%	60,951 $2.41 Million
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $71,926 - $99,608	-11,117 Reduced 42.54%	15,016 $101,000
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $63,663 - $88,340	6,360 Added 32.17%	26,133 $0
Q4 2018 Feb 14, 2019	SELL	$9.15 - $12.26 $282,991 - $379,177	-30,928 Reduced 61.0%	19,773 $215,000
Q3 2018 Nov 13, 2018	SELL	$10.49 - $13.72 $481,763 - $630,104	-45,926 Reduced 47.53%	50,701 $0
Q2 2018 Aug 10, 2018	BUY	$10.62 - $13.98 $826,214 - $1.09 Million	77,798 Added 413.18%	96,627 $0
Q1 2018 May 11, 2018	SELL	$5.9 - $14.99 $225,934 - $574,027	-38,294 Reduced 67.04%	18,829 $256,000
Q4 2017 Feb 09, 2018	BUY	$5.53 - $8.42 $59,414 - $90,464	10,744 Added 23.17%	57,123 $340,000
Q3 2017 Nov 09, 2017	BUY	$6.5 - $10.69 $301,463 - $495,791	46,379	46,379 $344,000

Others Institutions Holding CCXI

# of Institutions

Shares Held

66.3K

Call Options Held

Put Options Held

View Full List

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account